Clinigen Group

ERWINASE

Manufacturer:

Clinigen Group

Erwinase HCPCS:

J9019

HCPCS Code Descriptor:

Injection, asparaginase (erwinaze), 1,000 iu

Category:

J Code

Erwinase NDCs:

81561-0413-05

Primary Type:

Oncology

Generic/Specialty Status:

Single-Source

Package Type:

Vial

Route of Administration:

Injection

Erwinase CPT Codes:

Potential CPT administration codes for Erwinase can be found at the following link.

Potential NDC Listing Errors:

Our team has identified potential listing errors/discrepancies with the following NDCs:

81561-0413-05

About Erwinase:

ERWINASE is an Oncology drug manufactured by Clinigen Group and administered via the Injection route of administration. The J Code: J9019 is aligned to the drug ERWINASE.

ERWINASE is an asparagine-specific enzyme derived from Erwinia chrysanthemi used to treat acute lymphoblastic leukemia (ALL). It is most often used as one part of a multi-therapeutic regimen for ALL. ERWINASE (J9019) works by catalyzing the deamination of asparagine in leukemic cells, depriving them of any asparagine and causing cell death since leukemic cells do not synthesize their own asparagine. It is indicated for patients who have developed hypersensitivity to E. coli derived asparagine.

ACCESS PRICING AND MORE BY REGISTERING

J9019 Added Date:

January 1, 2013

J9019 Effective Date:

January 1, 2013

J9019 Termination Date:

HCPCS Active

We have not yet identified a manufacturer source of Erwinase billing and coding information.
Erwinase patient assistance information can be found through JazzCares at the URL: https://www.jazzpharma.com/our-purpose/patient-support/
ERWINASE prescribing information can be found at the link below:
Information regarding ERWINASE’s side effects can be found at MedlinePlus